EntryPoint Capital’s Immix Biopharma IMMX Stock Holding History

EntryPoint Capital’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,324	Closed	-$103K	–	871
2026 Q1	$103K	Buy	+11,324	New	+$83.2K	0.03%	702

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EntryPoint Capital's IMMX Position: Q2 2026 in Review

EntryPoint Capital sold out of Immix Biopharma (IMMX) in Q2 2026, closing a stake of 11,324 shares — an estimated $103K sold.

EntryPoint Capital first reported a position in IMMX in Q1 2026 and held it in 1 quarter. The position peaked at $103K in Q1 2026. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

EntryPoint Capital reported no remaining Immix Biopharma position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 11,324 Immix Biopharma shares in Q2 2026, an estimated $103K.
EntryPoint Capital first reported a position in Immix Biopharma in Q1 2026 and held it in 1 quarter.
EntryPoint Capital's Immix Biopharma position peaked at $103K in Q1 2026.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.